<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736655</url>
  </required_header>
  <id_info>
    <org_study_id>CIV-FR-18-07-024848</org_study_id>
    <nct_id>NCT03736655</nct_id>
  </id_info>
  <brief_title>Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma</brief_title>
  <acronym>SAFARI</acronym>
  <official_title>Non Randomised Multi-centered Study to Evaluate Safety and Efficacy of a Novel Interposition Supraciliary Implant in Glaucoma Patients Refractory to Topical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciliatech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciliatech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of a novel
      interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure
      (IOP) in patients with primary open angle glaucoma (POAG) who have failed at least one class
      of topical medical therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      68 patients will be included in this 5 years interventional study. All patients shall be
      indicated for glaucoma surgery alone (not combined with cataract), and will undergo
      incisional glaucoma therapy, including a novel simplified surgical technique allowing
      placement of an interposition supraciliary permanent device.

      Several patient data like IOP, visual capacity or associated pharmacological treatments will
      be recorded pre and post-operatively all along the follow-up.

      Purpose is to ensure device safety, and verify IOP and associated pharmacological treatment
      reduction after surgery, and evolution along follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess post-op IOP reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of Eyes With Intraocular Pressure (IOP) Reduction of ≥ 20%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess post-op IOP clinical success</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of Eyes With Intraocular Pressure (IOP) &lt; 21 mmHg</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Interposition supraciliary implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any patients corresponding to inclusion / exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interposition supraciliary implant</intervention_name>
    <description>Surgical placement of an interposition supraciliary implant in the supraciliary space</description>
    <arm_group_label>Interposition supraciliary implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of POAG Schafer 3 or 4

          -  Medicated IOP ≥ 21 and ≤ 30 mmHg

          -  Use of &gt; 2 topical IOP lowering medications

        Exclusion Criteria:

          -  Inflammatory, congenital, traumatic, neovascular, ICE syndrome, angle closure and
             Schaffer 1 and 2 glaucoma

          -  Previous incisional glaucoma surgery

          -  ALT / SLT or any ocular surgery in the last 6 months

          -  Non surgical interventional treatment (cyclophotocoagulation, ultrasounds, …)

          -  Medical treatment having intraocular hypotensive effect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier BENOIT</last_name>
    <phone>+33635550153</phone>
    <email>o.benoit@cilia.tech</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves LACHKAR, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

